key: cord-0863458-yuouf3dd
authors: Pawar, Manoj; Singh, Mehak
title: Systemic steroids and risk of fecal-oral shedding and increased transmission of SARS-Cov-2 in pemphigus cases()()
date: 2020-06-19
journal: Clin Dermatol
DOI: 10.1016/j.clindermatol.2020.06.006
sha: c093efa766ce8c1802b34a24df63ed44c5a77ab8
doc_id: 863458
cord_uid: yuouf3dd

Pemphigus and its variants, viz., vulgaris, foliaceous, vegetans, Ig A pemphigus, paraneoplastic pemphigus and Senear-Usher syndrome are rare autoimmune blistering diseases of the skin and/or mucous membranes. The autoantibodies involved in the pathogenesis of pemphigus against desmoglein result in the breach of the skin and mucosal barrier, which acts as the first line of defence against pathogens. In this paper we underscore the importance of the integumentary system as a shield against the acquisition as well as transmission of SARS-CoV-2 virion. We have also made an attempt to delineate the various treatment modalities available and the viral-drug dynamics involved in choosing the optimum therapeutic modality.

It is a general consensus that immunosuppressive or biologic treatment should be avoided in patients with active COVID-19 infection. 1 Rituximab, the only FDA-approved medication for moderate-to-severe PV, is considered first-line therapy for pemphigus; however, considering its irreversible effect on B-cells, which are active defence cells against COVID-19 infection, it is better to be avoided/postponed during this COVID pandemic. 2 Second option, which is a still commonly practiced and considered as the 1 st line therapy in resource poor settings, are corticosteroids -either in intravenous pulse doses or daily oral doses. Due to a complete lockdown situation, patients with pemphigus do not have ready access for monthly pulse steroid therapy, so that they may be maintained on an effective daily regimen of oral steroids; however, there are a few concerns about systemic steroids in pemphigus and the risk of transmission of COVID-19.

Severe or treatment naïve cases of PV have muco-cutaneous breaches which make them vulnerable to COVID-19 viral contagion as angiotensin-converting enzyme 2, which is a cell receptor for SARS-CoV-2, is abundantly present in the cutaneous blood vessels and the basal cell layer. 3 Once, pemphigus patient are infected with COVID-19, there is a high chance of increased viral shedding due to both gut barrier dysfunction and increased viral transmission, associated with "aerosolization" of infected faecal matter. 4 Recently, a theory for Corona virus entry into cell has been proposed i.e. antibody dependent enhancement, in which a neutralizing antibody binds to the surface spike protein of coronaviruses like a viral receptor, triggers a conformational change of the spike, and mediates viral entry into IgG Fc receptor-expressing cells through canonical viral-receptor-dependent pathways. We speculate that already primed immune system in PV with increased and marginalized T-cell and B-cell population at the active sites of PV may increase the virion uptake. Conversely, COVID-19 may increase the epitope spreading phenomenon in PV. leading to increased severity and J o u r n a l P r e -p r o o f hence a more vicious circle. 5 Managing pemphigus patients with a high viral load of COVID-19 may also increase the chances of nosocomial spread to healthcare workers.

The gut mucosal damage triggered by corticosteroids may increase the susceptibility of PV patients to the COVID-19, as feco-oral transmission has been established as a route of transmission of SARS-CoV-2. 4, 6 Corticosteroids are also linked to a disruption of microbiome leading a breach in the protective gut biological mantle. These protective bacteria serve as a biologic shield to combat the contagion. 6 Systemic steroids may cause breach in the biologic, physical, or even immunologic barriers of the gut, eventually leading to a so-called leaky gut, from which the viral particles could disseminate into the blood stream ( Figure 1 ). Opposed to this concept, the bioavailability and thus efficacy of oral steroids in pemphigus patients with mucosal involvement may be impaired due to gut mucosal dis-integrity and gut dysbiosis. 6, 7 Pemphigus patients with severe upper gastrointestinal and oral mucosal involvement may experience troublesome swallowing and associated decreased compliance. 7

Cortico-steroids can be considered a double-edged sword in the COVID-19 situation.

Systemic steroid induced immunosuppression impairs induction of IFN-1 responses to various respiratory viruses, including COVID-19, too. 8 In opposition, steroids have shown some beneficial effects in hyperinflammatory conditions associated with COVID-19 i.e. cytokine storm, acute respiratory distress syndrome, and sepsis. In any event , abrupt cessation of corticosteroids is not advised due to the risk of adrenal suppression. 9 A recent international registry has shown that patients with inflammatory bowel disease treated with corticosteroids had increased severity of COVID-19 , when compared to patients receiving such TNF-alpha antagonists as adalimumab (Humira®). 10 Physicians J o u r n a l P r e -p r o o f 

Anti 

Managing Cutaneous Immune-Mediated Diseases During the COVID

Treatment considerations for patients with pemphigus during the COVID-19 pandemic

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

COVID-19 and the gastrointestinal tract: more than meets the eye Gut Published Online First: 09

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

The effects of steroids upon the gastrointestinal tract

Study of upper gastrointestinal tract involvement in pemphigus by esophago-gastro-duodenoscopy

J o u r n a l P r e -p r o o f  Stay in home isolation for as long as possible with not more than one stint outside per day. Exercise extra precautions to minimise contact with others by keeping